

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: June 30, 2012
Estimated Average burden hours per response: 4.0

1. Issuer's Identity					
CIK (Filer ID Number)	Previous Name(s)	▼ None	Entity Ty	/ре	
0001439222			€ cor	poration	
Name of Issuer			~	nited Partnership	
AGIOS PHARMACEUTICALS INC			_	ited Liability Company	
Jurisdiction of			00E0		
Incorporation/Organization DELAWARE			_	neral Partnership	
Year of Incorporation/Organiza	tion		_	iness Trust	
Over Five Years Ago	шоп		Oth	er	
Within Last Five Veers	2007				
2. Principal Place of Bus	iness and Co	ntact Inform	ation		
Name of Issuer					
AGIOS PHARMACEUTICALS INC					
Street Address 1		Street Address 2			
38 Sidney Street		2nd Floor			
City	ate/Province/Country	ZIP/Postal Co	ode	Phone No. of Issuer	
CAMBRIDGE	IASSACHUSETTS	02139		617-649-8600	
3. Related Persons					
Last Name	First Name		Middle Na	ame	
Schenkein	David				
Street Address 1		Street Address 2			
38 Sidney Street		2nd Floor			
City	State/Province/Cou	ntry	ZIP/Postal	Code	
Cambridge MASSACHUSETTS 02139					
	1000		10-2		
Relationship: Execu	tive Officer	Director	1	Promoter	
Clarification of Response (if Necessary)					
Last Name	First Name		Middle Na	ame	
Higgons	Duncan				
Street Address 1	1	Street Address 2		1	
38 Sidney Street		2nd Floor			
City					
Cambridge	State/Province/Cou		ZIP/Postal	Code	

Relationship:	Execu	tive Officer	Director	Promoter	
Clarification of Response	e (if Necessa	ry)			
[
Last Name		Middle Name			
Nelsen		Robert		7	
Street Address 1	•		Street Address	2	
38 Sidney Street			2nd Floor		
City		State/Province/	Country	ZIP/Postal Code	
Cambridge		MASSACHUSETTS		02139	
			1		
Relationship:	Execu	tive Officer	Director	Promoter	
Clarification of Response	e (if Necessa	ry)			
Last Name		First Name		Middle Name	
Cole		Doug			
		Doug	Church Addus -		
Street Address 1			Street Address 2nd Floor	2	_
38 Sidney Street					
City	1	State/Province/		ZIP/Postal Code	
Cambridge		MASSACHUSETTS		02139	
Relationship:	Execu	tive Officer	☑ Director	Promoter	
Clarification of Response	e (if Necessa	rv)		1	
	(
Last Name		First Name		Middle Name	
Cantley		Lewis		C.	
Street Address 1			Street Address	2	_
38 Sidney Street			2nd Floor		
City		State/Province/Country		ZIP/Postal Code	
Cambridge	Cambridge		ETTS	02139	
Relationship:	Execu	tive Officer	✓ Director	Promoter	
	(15.1)	`			
Clarification of Response	e (if Necessa	ry)			
Last Name		First Name		Middle Name	
Starr	tarr				
Street Address 1			Street Address	2	
38 Sidney Street		2nd Floor			
City		State/Province/	Country	ZIP/Postal Code	
Cambridge	MASSACHUSETTS		02139		

Relationship:	itive Officer Director	Promoter
Clarification of Response (if Necessa	ary)	
4. Industry Group		
C Agriculture	Health Care	C Retailing
Banking & Financial Services	C Biotechnology	C Restaurants
C Commercial Banking	C Health Insurance	Tachnology
C Insurance	C Hospitals & Physicians	Technology
C Investing	Pharmaceuticals	Computers
C Investment Banking	Other Health Care	C Telecommunications
C Pooled Investment Fund		Other Technology
Other Banking & Financial		Travel
C Services	C Manufacturing	C Airlines & Airports
C Business Services	Real Estate	C Lodging & Conventions
Energy	Commercial	C Tourism & Travel Services
C Coal Mining	Construction	C Other Travel
C Electric Utilities	C REITS & Finance	C Other
C Energy Conservation	C Residential	
C Environmental Services	C Other Real Estate	
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range	Aggregate Not A	aget Value Bange
No Revenues	70.000	sset Value Range te Net Asset Value
\$1 - \$1,000,000	C \$1 - \$5,000,00	
\$1,000,001 - \$5,000,000	C \$5,000,001 - \$	
\$5,000,001 - \$25,000,000	C \$25,000,001 -	\$50,000,000
\$25,000,001 - \$100,000,000	C \$50,000,001 -	\$100,000,000
Over \$100,000,000	Over \$100,000	0,000
Decline to Disclose	C Decline to D	isclose
Not Applicable	C Not Applica	ble
· ·) and Exclusion(s) Claim	ed (select all that apply)
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504 (b)(1)(i)	Rule 506	
Rule 504 (b)(1)(ii)	Securities Act Section 4(6)	
Rule 504 (b)(1)(iii)	Investment Company Act S	
		-1-7
7. Type of Filing		
▼ New Notice Date of First S	Sale 2010-04-14	First Sale Yet to Occur
-	2010 01 17	0010 10100 00001
Amendment		
8. Duration of Offering		

Does the Issuer intend this offering to last more than one year? C Yes No
9. Type(s) of Securities Offered (select all that apply)
Pooled Investment Fund Interests Equity
Tenant-in-Common Securities Debt
Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside investor USD
12. Sales Compensation
Recipient CRD Number None
(Associated) Broker or Dealer ✓ None (Associated) Broker or Dealer CRD ✓ None Number
Street Address 2
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation All States
12 Offering and Calca Amounta
13. Offering and Sales Amounts
Total Offering Amount \$ 8823937 USD Indefinite
Total Amount Sold \$ 8823937 USD
Total Remaining to be \$ USD Indefinite
Clarification of Response (if Necessary)
14 Investors
14. Investors
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering Regardless of whether securities in the offering have been or may be
sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of s expenditure is not known, provide a					e amount of an
Sales Commissions	\$)	USD	Estimat	te
Finders' Fees	\$)	USD	☐ Estimat	te
Clarification of Response (if Necessa	ary)				
16. Use of Proceeds					
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount. \$ 0 USD					

Signature and Submission

Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
 described and undertaking to furnish them, upon written request, the information furnished to
 offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that the Issuer is not disqualified from relying on any Regulation D exemption it has identified in Item 6 above for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person. For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AGIOS PHARMACEUTICALS /s/ David Schenkein		David Schenkein	Chief Executive Officer	2010-04-16